Risks of Breast, Ovarian, and Contralateral Breast Cancer for $\textit{BRCA1}$ and $\textit{BRCA2}$ Mutation Carriers
Authors
Kuchenbaecker, K
Hopper, JL
Barnes, DR
Phillips, K-A
Mooij, TM
Roos-Blom, M-J
Jervis, S
van Leeuwen, FE
Milne, RL
Andrieu, N
Goldgar, DE
Terry, MB
Rookus, MA
Easton, DF
Antoniou, A
and the BRCA1 and BRCA2 Cohort Consortium
Publication Date
2017-06-20Journal Title
JAMA
ISSN
0098-7484
Publisher
American Medical Association
Volume
317
Issue
23
Pages
2402-2416
Language
English
Type
Article
This Version
AM
Metadata
Show full item recordCitation
Kuchenbaecker, K., Hopper, J., Barnes, D., Phillips, K., Mooij, T., Roos-Blom, M., Jervis, S., et al. (2017). Risks of Breast, Ovarian, and Contralateral Breast Cancer for $\textit{BRCA1}$ and $\textit{BRCA2}$ Mutation Carriers. JAMA, 317 (23), 2402-2416. https://doi.org/10.1001/jama.2017.7112
Abstract
$\textbf{Importance}$ The clinical management of $\textit{BRCA1}$ and $\textit{BRCA2}$ mutation carriers requires accurate, prospective cancer risk estimates.
$\textbf{Objectives}$ To estimate age-specific risks of breast, ovarian, and contralateral breast cancer for mutation carriers and to evaluate risk modification by family cancer history and mutation location.
$\textbf{Design, Setting, and Participants}$ Prospective cohort study of 6036 $\textit{BRCA1}$ and 3820 $\textit{BRCA2}$ female carriers (5046 unaffected and 4810 with breast or ovarian cancer or both at baseline) recruited in 1997-2011 through the International $\textit{BRCA1/2}$ Carrier Cohort Study, the Breast Cancer Family Registry and the Kathleen Cuningham Foundation Consortium for Research into Familial Breast Cancer, with ascertainment through family clinics (94%) and population-based studies (6%). The majority were from large national studies in the United Kingdom (EMBRACE), the Netherlands (HEBON), and France (GENEPSO). Follow-up ended December 2013; median follow-up was 5 years.
$\textbf{Exposures}$ $\textit{BRCA1/2}$ mutations, family cancer history, and mutation location.
$\textbf{Main Outcomes and Measures}$ Annual incidences, standardized incidence ratios, and cumulative risks of breast, ovarian, and contralateral breast cancer.
$\textbf{Results}$ Among 3886 women (median age, 38 years; interquartile range [IQR], 30-46 years) eligible for the breast cancer analysis, 5066 women (median age, 38 years; IQR, 31-47 years) eligible for the ovarian cancer analysis, and 2213 women (median age, 47 years; IQR, 40-55 years) eligible for the contralateral breast cancer analysis, 426 were diagnosed with breast cancer, 109 with ovarian cancer, and 245 with contralateral breast cancer during follow-up. The cumulative breast cancer risk to age 80 years was 72% (95% CI, 65%-79%) for $\textit{BRCA1}$ and 69% (95% CI, 61%-77%) for $\textit{BRCA2}$ carriers. Breast cancer incidences increased rapidly in early adulthood until ages 30 to 40 years for $\textit{BRCA1}$ and until ages 40 to 50 years for $\textit{BRCA2}$ carriers, then remained at a similar, constant incidence (20-30 per 1000 person-years) until age 80 years. The cumulative ovarian cancer risk to age 80 years was 44% (95% CI, 36%-53%) for $\textit{BRCA1}$ and 17% (95% CI, 11%-25%) for $\textit{BRCA2}$ carriers. For contralateral breast cancer, the cumulative risk 20 years after breast cancer diagnosis was 40% (95% CI, 35%-45%) for $\textit{BRCA1}$ and 26% (95% CI, 20%-33%) for $\textit{BRCA2}$ carriers (hazard ratio [HR] for comparing $\textit{BRCA2}$ vs $\textit{BRCA1}$, 0.62; 95% CI, 0.47-0.82; P=.001 for difference). Breast cancer risk increased with increasing number of first- and second-degree relatives diagnosed as having breast cancer for both $\textit{BRCA1}$ (HR for ≥2 vs 0 affected relatives, 1.99; 95% CI, 1.41-2.82; P<.001 for trend) and $\textit{BRCA2}$ carriers (HR, 1.91; 95% CI, 1.08-3.37; P=.02 for trend). Breast cancer risk was higher if mutations were located outside vs within the regions bounded by positions c.2282-c.4071 in $\textit{BRCA1}$ (HR, 1.46; 95% CI, 1.11-1.93; P=.007) and c.2831-c.6401 in $\textit{BRCA2}$ (HR, 1.93; 95% CI, 1.36-2.74; P<.001).
$\textbf{Conclusions and Relevance}$ These findings provide estimates of cancer risk based on $\textit{BRCA1}$ and $\textit{BRCA2}$ mutation carrier status using prospective data collection and demonstrate the potential importance of family history and mutation location in risk assessment.
Sponsorship
Funding sources include CRUK, ERC and NIHR. See articel for full list.
Funder references
Cancer Research UK (20861)
Cancer Research Uk (None)
Cancer Research Uk (None)
Cancer Research Uk (None)
Cancer Research Uk (None)
Cancer Research Uk (None)
Cancer Research Uk (None)
Cancer Research UK (23382)
European Research Council (310018)
European Commission (16563)
Embargo Lift Date
2100-01-01
Identifiers
External DOI: https://doi.org/10.1001/jama.2017.7112
This record's URL: https://www.repository.cam.ac.uk/handle/1810/264754
Rights
Licence:
http://www.rioxx.net/licenses/all-rights-reserved
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk